Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice - Concepedia

Concepedia

Publication | Open Access

Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice

DOI Full Paper Access

10

Citations

7

References

2020

Year

Selma Atalay, J. M. P. A. van den Reek, J.M.M. Groenewoud, P.C.M. van de Kerkhof, Wietske Kievit, E.M.G.J. de Jong

Journal of Dermatological Treatment

Abstract

The proposed dose reduction strategy is effective for a significant part of patients and remains safe up to 2 years of follow-up.

References

	Year	Citations

Page 1